Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
| ▸ | RPS6KA2 | Q15349 | 4/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3938873 | 0.93 | RPS6KA3 (0.45) | RPS6KA3PLA2G10RPS6KA2PLAUFGFR1 | |
| SCHEMBL50870 | 0.92 | POLB (0.39) | RPS6KA3RPS6KA2FGFR1CA12CA1 | |
| SCHEMBL51354 | 0.87 | DAO (0.38) | CA12CA9 | |
| SCHEMBL3946964 | 0.86 | RPS6KA2 (0.41) | RPS6KA3RPS6KA2PDK2ACSS2 | |
| SCHEMBL50820 | 0.82 | RPS6KA3 (0.49) | RPS6KA3PLA2G10RPS6KA2PLAUFGFR1 | |
| SCHEMBL5304198 | 0.78 | HPGD (0.45) | — | |
| SCHEMBL271134 | 0.78 | RPS6KA3 (0.46) | RPS6KA3PLA2G10RPS6KA2PLAUFGFR1 | |
| SCHEMBL4831504 | 0.76 | RPS6KA3 (0.40) | RPS6KA3RPS6KA2 | |
| SCHEMBL253105 | 0.74 | HTR1A (0.34) | — | |
| SCHEMBL4830051 | 0.74 | SMN1; SMN2 (0.37) | RPS6KA3RPS6KA2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473688-B2 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-06 | — | — | US | disclosed |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| WO-2007033175-A1 | INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | HTR3C, IDO1, HTR3B | RPS6KA3 2580/4885PLA2G10 3811/4885RPS6KA2 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.